NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/21/2023
Back to search
Official data from USPTO
ALLEGAXIN
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
18
Latest update
11/21/2023
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
03/05/2022
Registration date
11/21/2023
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/21/2023
Last transaction
11/21/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
07/29/2022
First use in commerce
07/29/2022
Drawing code
4
Owner type
99
Owner location
Shanghai, CN
Examiner
TATE-NAGHI, JACQUELINE P
Law office
N20
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Shanghai Affinity Biopharmaceutical Co.,Ltd.
Representatives
KEVIN O'KEEFE KEEFER-G
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Biological preparations for the treatment of cancer diseasescacinoma diseasesmalignant diseasesinfectious diseases; Chemical preparations for pharmaceutical or medical purposesfor musculo-skeletal disorderscancer diseasescacinoma diseasesmalignant diseases; Chemical preparations for pharmaceutical or medical purposesfor cancer; Drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical products for the prevention and treatment of cancer; Tumor suppressing agents
Publications
History of USPTO decisions and trademark events.
18 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
11/21/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
10/19/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
10/18/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
09/13/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
09/08/2023
IUAF
USE AMENDMENT FILED
08/30/2023
EISU
TEAS STATEMENT OF USE RECEIVED
08/30/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
03/21/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/24/2023
PUBO
PUBLISHED FOR OPPOSITION
01/24/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/04/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/16/2022
DOCK
ASSIGNED TO EXAMINER
12/16/2022
TAEA
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
03/12/2022
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
03/12/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/09/2022
NWAP
NEW APPLICATION ENTERED
03/09/2022
Continuous trademark protection
Get notified about every new filing that threatens ALLEGAXIN or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.